BeiGene to Participate in the LEERINK Partners 6th
Post# of 301275
CAMBRIDGE, Mass., Feb. 08, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the LEERINK Partners 6 th Annual Global Healthcare Conference in New York, NY. The presentation is scheduled for 1:00 PM ET on February 16, 2017.
A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/ . An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.
Investor/Media Contact Lucy Li, Ph.D. +1 781-801-1800 ir@beigene.com media@beigene.com
(0)
(0)